Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2023 16:05 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

- LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 - - Combined OPTIC...
June 12, 2023 08:00 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid

REDWOOD CITY, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
June 02, 2023 08:00 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference

REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
May 25, 2023 06:30 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Announces New Executive Leadership Roles

- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D., chief development officer, expands her responsibilities to lead Adverum’s...
May 18, 2023 09:00 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform

- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT...
May 18, 2023 09:00 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
May 11, 2023 16:05 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

- Full enrollment of the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD) is anticipated in the second half of 2023 - - LUNA 14-week data, including initial aflibercept protein...
May 10, 2023 16:05 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference

REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
May 02, 2023 16:30 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD

REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
April 23, 2023 13:00 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec

- Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in...